Carestream Health Medical Device Company Intelligence Report

Published:August 2011
No. of Pages: 34

Price: $515

 

   

Report Summary

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Carestream Health provides dental and medical imaging systems and healthcare information technology (IT) solutions; molecular imaging systems for the life science research and drug discovery/development market segments; and X-ray film and digital X-ray products for the non-destructive testing market. It also operates the Carestream Advanced Materials group, which is developing new film products for the printed electronics market, including solar-panel and touch-screen technology.

Carestream Health was formed in May 2007 following Onex Corporation's acquisition of Eastman Kodak's Health Group for US$2.35 billion. Carestream Health has licensed the Kodak brand for use with its own brands across its portfolio of medical imaging and healthcare IT products.

In 2010, Carestream Health generated revenues of US$2.3 billion and served a global customer base in 150 countries. Its revenues in the first six months of 2011 amounted to US$1.15 billion. The company employs approximately 7,425 people worldwide.

Onex is a Canada-based private equity group that trades publicly on the Canadian stock exchange. It owns a portfolio of companies that are active in a diverse range of industry segments, including: healthcare, electronics manufacturing services, aerostructures, financial services, customer support services, metal services and other businesses such as aircraft, commercial vehicles, gaming, building products and real estate. In addition to Carestream Health, Onex’ other healthcare interests consist of: Center for Diagnostic Imaging, a US provider of diagnostic and therapeutic radiology services; Skilled Healthcare Group, an organisation of skilled nursing and assisted living facilities operators in the US; and Res-Care, a leading provider of residential, training, educational and support services for people living with disabilities and special needs in the US, Canada and Europe. Onex completed the sale of its interest in Emergency Medical Services Corporation in May 2011.

This company report provides

Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation

Key Corporate Events

The report was produced as part of Medical Device Companies Analysis (MDCA). For more information on MDCA, click here.

Table of Contents
OVERVIEW .1
FINANCIAL REVIEW 2
First Half 2011 Financial Results 2
2010 Financial Results  .2
Five-Year Financial Data 5
Employees 6
STRATEGIC FOCUS  7
PRODUCTS 8
Medical Imaging and IT Solutions   9
Imaging 9
IT Solutions 12
Dental 16
Molecular Imaging 19
Non-Destructive Testing   .20
Carestream Advanced Materials   .20
RESEARCH AND DEVELOPMENT 22
Research Establishments 22
Carestream Centres of Excellence 22
MANUFACTURING 24
AGREEMENTS 26
PenRad Technologies 27
K-Dental   27
Darby Dental Supply 27
Apelem 27
Acacia Research 27
Technology Partners (IMAGINE Software) 27
Genesis Digital Imaging  28
Onconcepts 28
National Digital Medical Archive (NDMA)  28
Siemens Healthcare 29
Collaborative Medical Technology Corp (CMTC) 29
Médical Tronik Montreal  30
Hitachi 30
MedLink International   30
Confirma (Merge Healthcare) 30
Meridian Technique 30
IMTEC Imaging  30
Novadaq Technologies   .31
Medlink Imaging   .31
CompuMed 31
Viatronix   31
Cisco Systems   31
IBM 32
Questra (Axeda) 32
MERGERS AND ACQUISITIONS  33
Quantum Medical Imaging   33
Healthsoft Assets   33
Logicon Caries Detector Software 33
Orex 34
Algotec Systems 34
PracticeWorks  34
MiraMedica’s Computer-Aided Detection Technology  34
Lumisys 34
Computer Knowledge   .35
Imation’s Medical Imaging Business  35
Nova MicroSonics   .35
Vortech Data 35
DIVESTITURES   . 36
AuntMinnie.com 36
NanoSystems 36
Sterling Winthrop, Clinical Diagnostics and L&F Products   36
LITIGATION   37
Caliper 37
KEY CORPORATE EVENTS   38
List of Tables
SUMMARY OPERATING RESULTS iii
Recent Key Events  1
Carestream Health - First Half 2011 Financial Results  2
Kodak Health Group - Financial Results, 2005-2007   2
Carestream Health - Annual Financial Results, 2007-2010  3
Onex – Five-Year Financial Summary 5
Carestream Health’s Major Manufacturing Facilities, August 2011  .25
Agreements Summary   26
Mergers and Acquisitions Summary 33
List of Charts
Carestream Health - Annual Revenues and Gross Profit, 2008-2010  .3
Carestream Health - Annual Revenues by Product Area, 2007-2010  .4
Carestream Health - 2010 Product Sales by Business Area   8

Medistat Interactive

Published:August 2011

Price: $4365

   

Report Summary

Combining Espicom’s world class data with a state-of-the-art analysis tool, Medistat Interactive takes medical market evaluation to a new level.

Dashboard driven and rich in graphics, you can now easily mobilise key data, immediately compare and contrast key health indicators, infrastructure and market data for multiple markets at the click of a button. Track changes to historical/forecast data, export the data to other programs or create pdfs of charts and tables for inclusion in plans and presentations.

Whether it’s fast access through one of the many pre-defined tabs or the easy-to-use custom report builder, you have complete control over the data, making it work quickly for you.

For over 30 years, Espicom has been the leader in analysing medical device market and equipments worldwide. Its reputation as a provider of reliable and thorough information is well founded and its services are used by leading healthcare companies in more than 50 markets.

Key benefits & features of Medistat Interactive

Compare Key Indicators
How does per capita health spend compare in BRIC countries? What is the forecast market growth in orthopaedics in Poland, Czech Republic and Hungary? With Medistat Interactive you can easily compare any statistics for any number of countries.

Strategic Insights

Medistat Interactive provides the strategic intelligence to support key investment, business planning and marketing decisions.

Market Snapshots

Easily review all statistics and forecasts for a particular market.

Benchmarking

Assess your company’s performance against actual market figures or monitor regional/national sales offices and the work of specialist sales agents.

Medical Sector Analysis

With actual figures and reliable forecasts, use Medistat Interactive to view market data on specific medical technology areas in the context of other health indicators.

Track trends

Use Medistat Interactive to track trends in past performance and assess future prospects with our unique
5-year forecasts for key indicators.

Book a demonstration today

We are in the final stages of developing Medistat Interactive and the product will be ready for online demonstration in the coming weeks. Be among the first to review it by booking time for a demonstration where you can see the power of the product.

Molecular Imaging: A Market Coming of Age

Published:August 2011
No. of Pages: 290

Price: $1749

 

 

Report Summary

• Critical review of the market conditions, trends and challenges
• Unique market forecasts to 2015 by major sector
• Comprehensive and detailed competitive analysis of 75 leading players

The early vision for molecular imaging (MI) was that it would revolutionise clinical diagnostics and pharmaceutical research, allowing disease to be explored and identified with greater accuracy and long before physical symptoms were experienced. But economic recession and technical challenges have taken their toll on the speed at which that vision has become reality - until now. While for many years MI delivered more promise than profits, the signs are that new products, applications and increasing clinical/health payer acceptance will see the market accelerate in the medium term to achieve global sales of US$6 billion by 2015.

Strong fundamentals are driving growth

Despite cost pressures from reduced capital spending and lower reimbursement for some procedures, the molecular imaging market fundamentals remain solid and there are strong opportunities for growth within the MI industry. The increasing incidence of cancer, cardiovascular and neurological diseases means that demand for faster and more accurate diagnosis, as well as drug development and pre-clinical study efforts, will continue to accelerate in the coming years. In addition, imaging technologies will become more widely adopted as clinical evidence is established as to their benefits, and new technological innovations continue to be brought to market, particularly related to the MI of cancer and neurological diseases. In addition, the current lack of penetration for nuclear and molecular imaging in emerging economies such as China, India and Brazil is driving demand in these regions, where new nuclear imaging facilities are being set up and lower-cost systems are in demand.

Corporate manoeuvres

The industry is still developing but already companies in the medical diagnostic imaging equipment business such as Philips, Siemens and GE, and in the radiopharmaceutical and contrast agent market such as GE, Bracco, Covidien, Bayer and Lantheus Medical Imaging are taking leading positions. And opportunities for big Pharma are not being missed, with both Eli Lilly and AstraZeneca actively involved. As the market develops, expect more consolidation in the tussle for dominance.

This new report provides unique 5-year market forecasts

Molecular imaging is still a developing sector and the question is often asked what it will be worth commercially. For the first time, this report provides a 5-year evaluation of the market’s prospects and provides year-by year growth for key sectors:

Nuclear Imaging
Pre-Clinical Imaging Systems
Molecular Imaging End-Use Products Market
Radiopharmaceuticals

This report easily answers key business questions such as:

• Which sector of the molecular imaging market is expected to achieve global sales of US$3.5 billion in 2015?
• What steps are being taken to ensure availability of the key istope Mo-99?
• How is Gallium-68 being used to better understand cancer cell migration?
• What advantages does PET have over other imaging technologies?
• What challenges must be overcome to meet growing demand in emerging markets and how is this influencing developers?
• Which European company is developing nanoprobes which identify the expression of the HER2 protein and with whom is it collaborating?
• Which US company was granted a European patent in March 2011 for its contrast agent used in the diagnosis of deep vein thrombosis?
• Now approved in the US and EU, does Digirad’s portable nuclear system mark a move to distributed MI technologies?

Only one company offers a full suite of MI products - is this a competitive advantage and does it represent an opportunity for further entrants to provide whole-market service?
A complete analysis packed with market analysis, sector forecasts to 2015 and detailed company evaluations

This report delivers the most complete and critical appraisal of the market, products and companies operating in this fast-growing health sector

EXECUTIVE SUMMARY MOLECULAR IMAGING COMPANIES
For each company an evaluation is made of their financial performance/status, products, research areas and significant deals or strategic partnerships

BACKGROUND
Applications of MI
Neurological Disease
Oncology
Cardiovascular Disease
MI for Drug Development

MI Modalities
Hybrid MRI/PET Imaging
Tracers and Radiopharmaceuticals

CURRENT MARKET DYNAMICS
Major Market Players
Recent Developments in the SPECT Market
Recent Developments in the PET Market
Reimbursement and Regulatory Approval Issues

MARKET OUTLOOK
Molecular Imaging: Market Drivers, Restraints & Future Opportunities
Market Forecasts 2010 -2015
Nuclear Imaging
Pre-Clinical Imaging Systems
Molecular Imaging End-Use Products Market
Radiopharmaceuticals
Emerging Technologies
The Role of Academic Institutions
Collaborative Development Efforts
New Imaging Modalities
ABT Molecular Imaging
ABX
Advanced Accelerator Applications
Advanced Cyclotron Systems
Advanced Medical Isotope
Affibody
Agenix
AntiCancer
Aleres Pharmaceuticals
Aposense
ART Advanced Research Technologies
Astellas Pharma
AstraZeneca
Atreus Pharmaceuticals
Avid Radiopharmaceuticals (Eli Lilly)
Bayer HealthCare Pharmaceuticals
Bioscan
Biospace Lab
Bracco
Bruker Biospin
BV Cyclotron Vu
Caliper Life Sciences
Cardinal Health
Carestream Health
CellPoint
Covidien
Cyclopharma
Digirad
Dilon Diagnostics
DRAXIMAGE
Eckert & Ziegler
Eczacibaşi-Monrol Nuclear Products
Erigal
GE Healthcare
Guerbet
Hamamatsu Photonics
IBA (Ion Beam Applications)
Imaging Diagnostic Systems
ImaginAB
Immunomedics
INDEC Systems
IntraMedical Imaging
Kereos
Lantheus Medical Imaging
Lightools Research
Mediso Medical Imaging Systems
MiLabs
Molecular Insight Pharmaceuticals
Naviscan
Neoprobe
Neurologica
Nordion
Novelos Therapeutics (Cellectar)
NuView Life Sciences
OncoVision
PerkinElmer
Pharmalucence
Philips Healthcare
Positron
Proportional Technologies
Scintomics
Seno Medical Instruments
Shimadzu
Siemens Healthcare
Sofie Biosciences
Spectrum Dynamics
Triad Isotopes
UltraSPECT
United Pharmacy Partners
Visualsonics (Sonosite)
Wilex
Diagnostic Imaging Systems Market by Modality, 2010
Medical Imaging Market, 2005-10 (US$b)
Nuclear Imaging Equipment Market, 2007-10 (US$b)
Molecular Imaging Market by End-Use Product Type, 2010
Nuclear Imaging Equipment Market, 2010-15E (US$m)
Pre-Clinical Imaging Systems Market, 2010-15E (US$m)
Radiopharmaceuticals Market, 2010-15E (US$m)
Molecular Imaging End-Use Products Market, 2010-15E (US$m)
Astellas Pharma Cardiac Imaging Sales, 2008-10 (US$m)
Caliper Life Sciences - Revenue by Division, 2010
Covidien’s Imaging Sales, 2006-10 (US$m)
Digirad - Revenue by Division, 2010
Eckert & Ziegler - Revenue by Product Segment, 2010
GE Healthcare - Revenue by Product, 2010
IBA - Revenue by Business Unit, 2010
Lantheus Medical Imaging: Cardiolite Sales, 2008-10 (US$m)
Nordion - Revenue by Segment, 2010
Nordion: Medical Isotope Sales and Earnings, 2008-10 (US$m)
Philips Healthcare - Revenue by Segment, 2010
Philips Healthcare - Revenue by Region, 2010
Siemens Healthcare: Sales by Division, 2010

Trends and challenges - make sure you are fully briefed on the issues which are shaping the market...

Are the cost benefits of molecular imaging being recognised? Health payers, in the midst of an economic downturn, are focused on limiting immediate costs and this has impacted expansion and reimbursement of several imaging procedures. But advanced imaging enables detection and diagnosis at earlier stages of disease development, enabling treatment to begin before disease becomes systemic or established and reducing costs for invasive surgery or later-stage drug treatments. Similarly, there is much concern over the cost of new drugs, many of which may be used without the most accurate diagnostic insight into the underlying pathology of the disease. Molecular imaging’s advanced ability to evaluate disease at the molecular level has a critical role to ensure that only appropriate medicines are administered. Evidence is still building, but health payers would be wise to consider future molecular imaging technology as a benefit and not a cost in their financial plans.

Molecular Imaging - only for the big boys?

Although MI technologies hold great promise and market potential, there are significant barriers to market entry for companies, including the significant capital investments required to develop such products and get them through the lengthy and costly regulatory approval process. Adding to the challenge has been the difficult economic environment in recent years, which has limited the ability of start-up companies to raise capital from financial institutions or attract investment. Despite a difficult market for start-ups, the strong growth potential of MI technologies is providing good opportunities for companies with cash or financing available to them to add to their MI operations or enter this market, both through acquisitions or by licensing technologies from companies that cannot afford to commercialise them themselves.

A case in point...

Alzheimer’s disease imaging is currently a major area of opportunity, both in terms of helping to achieve a clinical diagnosis for a condition that can currently only be diagnosed at autopsy and also for pharmaceutical companies developing drugs to treat the condition. Previously privately-held, Avid Radiopharmaceuticals was acquired by the multi-national pharmaceutical company, Eli Lilly and Company, in December 2010. Avid’s lead MI agent, Amyvid, is being developed to diagnose Alzheimer’s disease and is expected to become the first MI agent for Alzheimer’s disease to be FDA-approved later in 2011. There are plenty of examples where smaller companies have ceased trading or changed status - investment capital is crucial to innovation, and how much of that comes from big Pharma will be closely watched.

In research...new imaging modalities

MI is driven by technical innovation. New modalities in research include GMI’s dual modality MRI/SPECT system, Philip’s Magnetic Particle Imaging platform for imaging nanoparticle concentrations in blood and GE’s 13C Hyperpolarised metabolic MR, which produces real-time, quantitative data regarding the presence and aggressiveness of tumours.

Cooper Companies Medical Device Company Intelligence Report

Published:July 2011
No. of Pages: 36
Price: $515


 

Report Summary

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

The Cooper Companies manufactures and markets speciality healthcare products through its CooperVision and CooperSurgical divisions.

CooperVision (CVI), headquartered in Pleasanton, California, US, manufactures and markets a broad range of contact lenses and, following its acquisition of Ocular Sciences in 2005, became one of the most successful players in this market. CVI’s primary offices are in the US and the UK and its manufacturing facilities are located in the US, the UK and Puerto Rico. Its principal medical device markets are the US, Europe and the Asia-Pacific region.

CooperSurgical (CSI), based on Trumbull, Connecticut, US, manufactures and markets medical devices, diagnostic products and surgical instruments and accessories for women’s healthcare, which are primarily used by gynaecologists and obstetricians. The company has mainly developed through small acquisitions, purchasing over 30 businesses over the last 20 years. The most recent acquisition was in April 2011, when CSI acquired Apple Medical, a developer of obstetric and gynaecology products. CSI’s primary objective is to service the obstetricians and gynaecologists in the US, since the company believes this is a more US-centric profession. However, the company does have a presence in Europe.
CVI’s three largest competitors are Johnson & Johnson’s Vistakon division, CIBA Vision (owned by Novartis) and Bausch & Lomb. Together with CVI, these companies represent almost 95% of the global soft contact lens market.

CSI competes primarily with smaller technology-driven companies that generally offer only one or two product lines. However, the company is now expanding into the significantly larger hospital and out-patient surgical procedure market, which is dominated by larger competitors such as Johnson & Johnson’s Ethicon Endo-Surgery and Ethicon Women’s Health and Urology companies, Boston Scientific, Gyrus ACMI (an Olympus company) and Covidien.

For the financial year ended 31st October 2010 (fiscal 2010), The Cooper Companies reported net income of US$112.8 million on net sales of US$1,158.5 million. This represented increases of 12% and 7%, respectively, when compared with fiscal 2009. CVI generated 84% of The Cooper Companies’ revenue, while CSI accounted for the remaining 16% of net sales.

As of June 2011, The Cooper Companies had a total of approximately 7,100 employees.

This company report provides

Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation

Key Corporate Events

The report was produced as part of Medical Device Companies Analysis (MDCA). For more information please click on the link to, Medical Device Companies Analysis.

Table Of Contents

OVERVIEW.1

FINANCIAL REVIEW 2
First Half Fiscal Year 2011 Financial Results.2
CVI.3
CSI.4
Fiscal Year 2010 Financial Results5
CVI.6
CSI.8
Five-Year Financial Data9
Outlook10
Employees.11

STRATEGIC FOCUS12

PRODUCTS13
CVI13
CSI.16

RESEARCH AND DEVELOPMENT.22

MANUFACTURING AND DISTRIBUTION23
Manufacturing.23
Distribution.23

AGREEMENTS 24
CIBA Vision.24
Gebauer Medizintechnik24
Advanced Medical Optics.25
Rohto Pharmaceutical Company.25
Eyefinity.25
Welch Allyn25

MERGERS AND ACQUISITIONS 26
Apple Medical27
Asahikasei Aime Assets.27
American Medical Systems Assets.27
JLJ Medical Devices International27
Intuitive Surgical's Uterine Positioning System27
Wallach Surgical Devices28
Lone Star Medical Products28
NeoSurg Technologies/Inlet Medical28
Ocular Sciences28
Opti-Centre29
Milex Products.29
Argus Biomedical’s AlphaCor and AlphaSphere Products.29
SURx’ Radiofrequency Bladder Neck Suspension Technology29
Avalon Medical30
Prism Enterprises.30
SAGE BioPharma30
Ackrad Laboratories30
Orthometrix/Norland Medical Systems’ Bone Densitometry Business31
Biocompatibles Eye Care31
Medscand Medical.31
CL-Tinters Oy32
MedAmicus’ LuMax Fiber Optic Cystometry System32
MedaSonics32
Leisegang Medical’s Women’s Healthcare Products.32
BEI Medical Systems’ Women’s Healthcare Products.32
Aspect Vision Care Ltd.33
Marlow Surgical Technologies.33
Unimar33
RUMI Uterine Manipulator.33

MINORITY INVESTMENTS.34
Quidel.34

DIVESTITURES 35
CooperVision Surgical.35
Quidel.35
Hospital Group of America.35

LITIGATION.36
Rembrandt Vision Technologies .36
Internal Revenue Service36
Securities Litigation36

KEY CORPORATE EVENTS37

List of Tables

SUMMARY OPERATING RESULTS.iii
Recent Key Events1
The Cooper Companies – First Half Fiscal 2011 Financial Results.2
The Cooper Companies – First Half Fiscal 2011 Net Sales by Geographic Region.2
CVI – Selected First Half Fiscal 2011 Financial Results3
CVI – First Half Fiscal 2011 Revenues By Key Product.3
CVI – First Half Fiscal 2011 Sales by Geographic Area.3
CSI – Selected First Half Fiscal 2011 Financial Results.4
The Cooper Companies – Annual Financial Results, Fiscal Years 2006-2010.5
The Cooper Companies – Annual Net Sales by Geographic Region, Fiscal Years 2006-2010 5
CVI – Selected Annual Financial Results, Fiscal Years 2008-20106
CVI – Annual Revenues By Key Product, Fiscal Years 2008-2010.7
CVI – Annual Revenues by Geographic Region, Fiscal Years 2008-20107
CSI – Selected Annual Financial Results, Fiscal Years 2008-2010.8
The Cooper Companies – Five-Year Financial Summary, Fiscal Years 2006-2010.9
Soft Contact Lens Market by Region and by Competitor, Q1 201114
Global Soft Lens Market – Modality Breakdown by Region, Q1 201114
Global Soft Contact Lens Market – Estimated Five-Year Sales Trend by Product, Calendar Year 2010-2015  15
Global Soft Contact Lens Market – Estimated Five-Year Sales Trend by Region, Calendar Year 2010-2015 15
CVI – Key Contact Lens Brands, July 2011.15
CSI Market Shares, Fiscal Year 200918
CooperSurgical – Key Products, July 201119
Cooper Companies – Annual R&D Expenditure, Fiscal Years 2008-2010.22
Agreements Summary24
Mergers and Acquisitions Summary.26

List of Charts

The Cooper Companies - Annual Net Sales and Operating Income, Fiscal Years 2006-2010  5
The Cooper Companies - Annual Net Sales by Geographic Region, Fiscal Years 2006-2010.6
CVI - Annual Sales and Operating Income, Fiscal Years 2008-2010.6
CVI - Annual Net Sales by Geographic Area, Fiscal Years 2008-20107
CSI - Annual Net Sales and Operating Income, Fiscal Years 2008-2010.8
Global Soft Contact Lens Market by Competitor, Q1 2011.14
CSI – Office-based Sales by Product Type, Fiscal 201016
CSI – Hospital Sales by Medical Procedure/Segment, Fiscal 201017
CSI – Fertility Clinic Sales by Product Type, Fiscal 2010.17